Latest revision as of 18:03, 25 March 2024
|-
| Valsartan
| Diovan
| 6
| 2–4 hrs
| 95%
| 25%
| 30/70%
| Yes
| 80–320
| Substrates: MRP2 and OATP1B1/SLCO1B1
|-
| Irbesartan
| Avapro
| 11–15
| 1.5–2 hrs
| 90–95%
| 70%
| 20/80%
| No
| 150–300
| Minor substrates of CYP2C9
|-
| Telmisartan
| Micardis
| 24
| 0.5–1 hr
| >99%
| 42–58%
| 1/99%
| No
| 40–80
| None known; >97% via biliary excretion
|-
| Eprosartan
| Teveten
| 5
| 1–2 hrs
| 98%
| 13%
| 30/70%
| No
| 400–800
| None known; >90% via renal and biliary excretion
|-
| Olmesartan
| Benicar/Olmetec
| 14–16
| 1–2 hrs
| >99%
| 29%
| 40/60%
| No
| 10–40
| Substrates of OATP1B1/SLCO1B1
|-
| Azilsartan
| Edarbi
| 11
| 1.5–3 hrs
| >99%
| 60%
| 55/42%
| No
| 40–80
| Minor substrates of CYP2C9
|-
| Fimasartan
| Kanarb
| 7–11
| 0.5–3 hrs after dosing.
| >97%
| 30–40%
| –
| –
| 30–120
| None known; primarily biliary excretion
|-
! Drug
! Trade name
! Biological half-life [hrs]
! Peak plasma concentration [Tmax]
! Protein binding [%]
! Bioavailability [%]
! Renal/hepatic clearance [%]
! Food effect
! Daily dosage [mg]
! Metabolism/transporter
|}